In our Nuclear Medicine Department, we both use diagnostic and therapeutic procedures using radioactive materials called radiopharmaceuticals.

What therapeutic procedures are used in our Nuclear Medicine Department?

• Peptide Receptor Radionuclide Therapy (PRRT)

PRRT is a kind of internal radiotherapy used to treat neuroendocrine tumors (NETs). Radiopharmaceuticals, such as Lutetium-177 DOTA TATE, are administered intravenously and circulate in the bloodstream. It attaches to the somatostatin receptors on the NET cells. After binding to the target receptors, it delivers destructive radiation and destroys or damages the cancer cells while minimizing the impact on surrounding healthy tissue.

• Lutetium-177 PSMA

Utilized in our department, Lutetium-177 PSMA therapy mirrors the PRRT process. This treatment is applied in cases of advanced prostate cancers, with a specific focus on targeting the PSMA (prostate-specific membrane antigen) molecule found on the surface of prostate cancer cells. The amount of this specific protein increases in prostate cancer cells. Once the radiopharmaceutical (in this case, Lutetium-177 PSMA) is injected intravenously, it attaches to the PSMA receptors on the cancer cells and delivers radiation that damages the targeted cancer cells.

For more information and a medical evaluation, please complete the form to contact us.